ライフサイエンスコーパス: lipoprotein lipase

1 by tetrahydrolipstatin (THL, an inhibitor of lipoprotein lipase).

2 retention in Bruch's membrane is mediated by lipoprotein lipase.

3 id metabolism, e.g. serum protein Igfbp1 and lipoprotein lipase.

4 onectin, perilipin, fatty acid synthase, and lipoprotein lipase.

5 hat was a poorer substrate for hydrolysis by lipoprotein lipase.

6 that shed adipocyte syndecans associate with lipoprotein lipase.

7 via their ability to inhibit the activity of lipoprotein lipase.

8 hed syndecan ectodomain can stabilize active lipoprotein lipase.

9 ruses expressing the mutant apoA-I and human lipoprotein lipase.

10 th a recombinant adenovirus expressing human lipoprotein lipase.

11 triglycerides, whose activity is enhanced by lipoprotein lipase.

12 ide levels and no inhibition of lipolysis by lipoprotein lipase.

13 p-regulation of those for hepatic lipase and lipoprotein lipase.

14 uscle cell-derived matrix in the presence of lipoprotein lipase.

15 e proliferator-activated receptor gamma2 and lipoprotein lipase.

16 egraded atherogenic lipoproteins enriched in lipoprotein lipase.

17 at are sensitive to the action of the enzyme lipoprotein lipase.

18 PTL4) has been identified as an inhibitor of lipoprotein lipase.

19 lipoprotein binding protein1's other ligand, lipoprotein lipase.

20 3 (ANGPTL3) inhibits lipolysis by binding to lipoprotein lipases.

21 lation of lipid is due to an upregulation of lipoprotein lipase (20-fold) and Cd36 (167-fold) and dow

22 othelial cells is thought to be required for lipoprotein lipase actions.

23 le, lipoprotein lipid composition, or HL and lipoprotein lipase activities.

24 e genetic disorder that is caused by loss of lipoprotein lipase activity and characterized by chylomi

25 e impaired clearance occurred despite normal lipoprotein lipase activity and likely reflected feedbac

26 uated plasma free fatty acids and attenuated lipoprotein lipase activity consistent with hallmarks of

27 Lipoprotein lipase activity in a given tissue is the rat

28 d was associated with increased postprandial lipoprotein lipase activity in adipose tissue.

29 treatment did not significantly alter basal lipoprotein lipase activity in renal transplant patients

30 f hepatic VLDL production as well as lowered lipoprotein lipase activity in serum compared with wild-

31 so associated with a substantial increase in lipoprotein lipase activity in the liver, which may have

32 n metabolism: liver-derived Angptl3 inhibits lipoprotein lipase activity primarily in the fed state,

33 Heparin-induced lipoprotein lipase activity was significantly lower in t

34 density lipoproteins is not due to perturbed lipoprotein lipase activity, a major culprit of isolated

35 adds ApoC-I and ApoC-II, major modulators of lipoprotein lipase activity, and confirms previously dem

36 giopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein lipase activity, increasing triglycerides an

37 d TG emulsion, despite increased postheparin lipoprotein lipase activity.

38 two members of this superfamily that inhibit lipoprotein lipase activity.

39 ma triglyceride levels but not in inhibiting lipoprotein lipase activity.

40 density lipoprotein levels by inhibition of lipoprotein lipase activity.

41 eparin plasma, of these mice contained human lipoprotein lipase activity.

42 FA storage factors than from adipose tissue lipoprotein lipase activity.

43 oxyacyl-CoA dehydrogenase (HADH) and adipose lipoprotein lipase (aLPL) activity, along with a decreas

44 ulin, adipocytes are known to secrete active lipoprotein lipase, an enzyme that binds to heparan sulf

45 Activation of lipoprotein lipase, an enzyme that is inhibited by angio

46 genes functionally related to APOA5, namely lipoprotein lipase and apolipoprotein C-III.

47 , both through the biochemical inhibition of lipoprotein lipase and by interfering with lipoprotein b

48 asma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or

49 capillaries, and the fact that GPIHBP1 binds lipoprotein lipase and chylomicrons suggest that GPIHBP1

50 ANGPTL3 has been reported to inhibit lipoprotein lipase and endothelial lipase, thereby incre

51 h the up-regulation of target genes, such as lipoprotein lipase and glutathione S-transferase alpha-2

52 ion of lipid detoxification enzymes, such as lipoprotein lipase and glutathione S-transferase alpha-2

53 The mRNA abundance for lipoprotein lipase and glyceraldehyde-3-phosphate dehydr

54 Furthermore, lipoprotein lipase and hepatic lipase activities were no

55 cations, that Lmf1 interacts physically with lipoprotein lipase and hepatic lipase and localizes the

56 ring the levels and activity of key enzymes (lipoprotein lipase and hepatic lipase) responsible for t

57 other two major members of this gene family, lipoprotein lipase and hepatic lipase, and has implicati

58 Recent studies indicate that in addition to lipoprotein lipase and hepatic lipase, the maturation of

59 ional attainment of enzyme activity for both lipoprotein lipase and hepatic lipase.

60 in plasma lipoproteins, which also includes lipoprotein lipase and hepatic lipase.

61 ow that intravascular lipolysis by adipocyte lipoprotein lipase and hepatic uptake of HDL by scavenge

62 mediated inhibition of both TG hydrolysis by lipoprotein lipase and hepatic uptake of remnant lipopro

63 We observed elevations in lipoprotein lipase and hypophosphatemia that were possib

64 the most compelling evidence revolves around lipoprotein lipase and its endogenous facilitator (APOA5

65 some 8 between D8S1130 and D8S1106, near the lipoprotein lipase and macrophage scavenger receptor gen

66 explained by increased expression of hepatic lipoprotein lipase and reduced expression of microsomal

67 syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed

68 Acute hepcidin administration down-regulated lipoprotein lipase and up-regulated Socs3 in visceral ad

69 bolism by increasing the gene expression for lipoprotein lipase and very-low-density lipoprotein rece

70 on and gene expression of bone sialoprotein, lipoprotein lipase, and fatty acid binding protein 4 are

71 lipolytic enzymes (hormone-sensitive lipase, lipoprotein lipase, and fatty acid binding protein 4) ve

72 the lipase gene family, hepatic lipase (HL), lipoprotein lipase, and pancreatic lipase, HL exhibits t

73 e-sensitive lipase, monoacylglycerol lipase, lipoprotein lipase, and patatin domain-containing phosph

74 FoxO1 in turn can regulate CD36, lipoprotein lipase, and PDK4, reinforcing the action of

75 synthase, as well as other adipogenic genes, lipoprotein lipase, and peroxisome proliferator-activate

76 he tissue with the most robust expression of lipoprotein lipase, and recent data attest to the import

77 rts of transgenic mice expressed the altered lipoprotein lipase, and the protein localized to the sur

78 ibits a key enzyme of lipoprotein clearance, lipoprotein lipase, and up-regulates a lipoprotein lipas

79 ipid transport and metabolism-related genes (lipoprotein lipase, apolipoprotein A1, apolipoprotein A4

80 idopteran ESP/YP2s, higher-dipteran YPs, and lipoprotein lipases are indeed homologous.

81 of monitoring fatty acid uptake and identify lipoprotein lipase as a potential therapeutic target in

82 e physiological extracellular chaperones for lipoprotein lipase as it translocates from its site of s

83 VLDL are hydrolyzed by lipoprotein lipase at the blood-endothelial cell interfa

84 ed a cell surface-associated beta-lactamase, lipoprotein, lipase, autolysin, and an ABC transporter l

85 cted with GPIHBP1 bind both chylomicrons and lipoprotein lipase avidly.

86 an flies), a class of proteins homologous to lipoprotein lipases called yolk polypeptides (YP) are ac

87 p-nitrophenyl-alpha-glucopyranoside and the lipoprotein lipase-catalyzed ester hydrolysis of resoruf

88 -stimulated expression of the genes encoding lipoprotein lipase, CD36, LXR alpha, and ABCG1 in thiogl

89 rs a 5-fold reduction in its ability to bind lipoprotein lipase compared to untreated apoC-II.

90 a B, and have been approved for treatment of lipoprotein lipase deficiency in Europe.

91 therapy product Glybera for the treatment of lipoprotein lipase deficiency.

92 erotype 1 (AAV1) vector for the treatment of lipoprotein lipase deficiency.

93 Wild-type or lipoprotein lipase-deficient mice were injected with low

94 Lipoprotein lipase-dependent adipocyte lipogenesis was a

95 docrine or autocrine/paracarine inhibitor of lipoprotein lipase depending on its sites of expression.

96 urements, we have assessed the regulation of lipoprotein lipase-derived fatty acid entrapment in subc

97 Lipoprotein lipase distribution was assessed in AMD samp

98 Thus, lipoprotein lipase expressed on the surface of cardiomyo

99 Cs, in part, by driving endothelial CD36 and lipoprotein lipase expression and facilitate FA transpor

100 Lipoprotein lipase expression in the arterial wall also

101 In contrast, macrophage lipoprotein lipase expression is significantly repressed

102 protein 1 (GPIHBP1), the molecule that moves lipoprotein lipase from the interstitial spaces to the c

103 is applied to data from a region within the lipoprotein lipase gene and the amount of detected recom

104 Using the lipoprotein lipase gene as an example, we evaluate new a

105 ear factor-3 site created in intron 8 of the lipoprotein lipase gene by a common single-nucleotide po

106 (EL) is a recently discovered member of the lipoprotein lipase gene family that hydrolyzes HDL phosp

107 of endothelial lipase (EL), a member of the lipoprotein lipase gene family, markedly reduces HDL-C l

108 se discovery rate [FDR], P<0.0001), an N291S lipoprotein lipase gene polymorphism (OR, 3.09; 95% CI,

109 a was investigated further by studies on the lipoprotein lipase gene.

110 Spillover of lipoprotein lipase-generated fatty acids from chylomicro

111 e FFA appearance and fractional spillover of lipoprotein lipase-generated fatty acids.

112 e, subfamily A (ABC1), member 1 (ABCA1), and lipoprotein lipase genes predicted to be damaging were i

113 type lipoprotein lipase, whereas an inactive lipoprotein lipase had a smaller effect.

114 To study whether nontransferable lipoprotein lipase has physiological actions, we placed

115 Although hepatic lipase and lipoprotein lipase have been shown to function as homodi

116 These dimeric lipases include lipoprotein lipase, hepatic lipase and endothelial lipas

117 of a selected group of lipases that include lipoprotein lipase, hepatic lipase and endothelial lipas

118 iver and increased plasma enzyme activity of lipoprotein lipase, hepatic lipase, and phospholipid tra

119 ms within the genes for apoE, apoB, apoCIII, lipoprotein lipase, hepatic lipase, endothelial lipase,

120 of new molecules that affect the activity of lipoprotein lipase holds great potential for novel thera

121 ARalpha mice with mice deficient for cardiac lipoprotein lipase (hsLpLko).

122 Lipoprotein lipase hydrolyses triglycerides in chylomicr

123 Spillover of fatty acids released by lipoprotein lipase hydrolysis of meal triglycerides may

124 Given the central role of lipoprotein lipase in energy metabolism, the discovery o

125 he expression of the glucose transporter and lipoprotein lipase in peripheral tissues, which is respo

126 sue, in that all the fatty acids released by lipoprotein lipase in skeletal muscle are taken up by th

127 that is associated with increased levels of lipoprotein lipase in the Rad tg mice.

128 e proliferator-activated receptor-gamma2 and lipoprotein lipase) in human MSCs after 21 days of treat

129 PRE-bound PV on a PPARgamma-target gene, the lipoprotein lipase, in vivo, suggesting the dominant act

130 increase in adipose Angptl4 and the ensuing lipoprotein lipase inactivation may contribute to athero

131 ed adipose Angptl4 levels, inhibited adipose lipoprotein lipase, increased fasting levels of plasma t

132 mice was associated with fatty acid-mediated lipoprotein lipase inhibition and changes in a PPARgamma

133 POC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemi

134 mice established that Fiaf is a circulating lipoprotein lipase inhibitor and that its suppression is

135 induced adipose factor (Fiaf), a circulating lipoprotein lipase inhibitor whose expression is normall

136 ance, lipoprotein lipase, and up-regulates a lipoprotein lipase inhibitor, angiopoietin-like 4 (Angpt

137 easured following tyloxapol (an inhibitor of lipoprotein lipase) injection.

138 Although lipoprotein lipase is expressed by and is found on the s

139 III (apo C III), a competitive inhibitor of lipoprotein lipase is increased in CKD.

140 Lipoprotein lipase is the principal enzyme that hydrolyz

141 Lipoprotein lipase is transported as a stable enzyme fro

142 uced adipose factor), a protein inhibitor of lipoprotein lipase, is synthesized and secreted during f

143 We used heart-specific lipoprotein lipase knock-out mice (hLpL0) to test whethe

144 Human AMD samples had lipoprotein lipase labeling within drusen, basal deposit

145 nd E), enzymes involved in lipid processing (lipoprotein lipase, lecithin cholesteryl ester transfera

146 The effects of n-3 FA on modulating arterial lipoprotein lipase levels link to changes in lipid depos

147 hormone-sensitive lipase (HSL) (84 kDa) and lipoprotein lipase (LPL) (56 kDa), respectively.

148 f the cellular regulation of skeletal muscle lipoprotein lipase (LPL) (a protein important for contro

149 er in b/b than +/b rats due to reduced serum lipoprotein lipase (LPL) activity (3.1 vs. 5.0 mM/min; P

150 Angptl4 inhibits extracellular lipoprotein lipase (LPL) activity and stimulates the lip

151 a significant increase of postheparin plasma lipoprotein lipase (LPL) activity compared with mice tha

152 m triglycerides, markers of lipogenesis, and lipoprotein lipase (LPL) activity in adults participatin

153 We have examined the regulation of lipoprotein lipase (LPL) activity in skeletal muscle dur

154 Both proteins were found to suppress lipoprotein lipase (LPL) activity in vitro as well as in

155 of which have recently been shown to inhibit lipoprotein lipase (LPL) activity in vivo.

156 roduction but suppresses post-heparin plasma lipoprotein lipase (LPL) activity suggesting that the hy

157 on were unchanged in ppHF dams, but systemic lipoprotein lipase (LPL) activity was increased, suggest

158 Myocardial heparin-releasable lipoprotein lipase (LPL) activity was moderately increas

159 ins (apo) C-I and C-III are known to inhibit lipoprotein lipase (LPL) activity, but the molecular mec

160 d to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation

161 in-like 4 (ANGPTL4), a protein that inhibits lipoprotein lipase (LPL) activity, is highly expressed i

162 n of the transgene and inhibition of cardiac lipoprotein lipase (LPL) activity.

163 ity lipoprotein secretion and an increase in lipoprotein lipase (LPL) activity.

164 re deficient in adipose tissue expression of lipoprotein lipase (LpL) also have less fat, but only wh

165 We also detect lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) h

166 t the genes with highest scores were: ABCA1, lipoprotein lipase (LPL) and cholesterol ester transfer

167 se tissue, and GPIHBP1-expressing cells bind lipoprotein lipase (LPL) and chylomicrons avidly.

168 Lipoprotein lipase (LPL) and endothelial lipase (EL), th

169 glyceride lipase gene family, which includes lipoprotein lipase (LpL) and hepatic lipase (HL).

170 In this report, we show that RAP binds to lipoprotein lipase (LPL) and may play a role in the matu

171 de-rich lipoproteins to remnant particles by lipoprotein lipase (LPL) and their uptake by the liver.

172 GPI-anchored endothelial cell protein, binds lipoprotein lipase (LPL) and transports it into the lume

173 oprotein C-II (apoC-II) is the co-factor for lipoprotein lipase (LPL) at the surface of triacylglycer

174 the lymphocyte antigen 6 (Ly6) family, binds lipoprotein lipase (LPL) avidly and is required for the

175 Lipoprotein lipase (LpL) binding to heparan sulfate prot

176 (AAV-1)-mediated gene transfer to muscle for lipoprotein lipase (LPL) deficiency, 1 subject from the

177 rting receptor, capturing the soluble enzyme lipoprotein lipase (LPL) during export from the TGN.

178 The lipoprotein lipase (LPL) enzyme expressed by macrophages

179 cles hydrolyzed in vitro through addition of lipoprotein lipase (LpL) exhibit strikingly similar chan

180 We investigated in vivo whether lipoprotein lipase (LPL) facilitates the placental uptak

181 ein of capillary endothelial cells, shuttles lipoprotein lipase (LPL) from subendothelial spaces to t

182 endothelial membrane protein that transports lipoprotein lipase (LPL) from the subendothelial space t

183 an endothelial cell protein that transports lipoprotein lipase (LPL) from the subendothelial spaces

184 that included human Chromosome 21, the human lipoprotein lipase (LPL) gene locus and the multi-locus

185 evant published datasets including the human lipoprotein lipase (LPL) gene locus, the human Y-chromos

186 3702T>C) in the 3'untranslated region of the lipoprotein lipase (LPL) gene.

187 otein-TAG may gain access to target cells by lipoprotein lipase (LPL) hydrolysis or via receptor-medi

188 Lipoprotein lipase (LPL) hydrolyzes fatty acids (FAs) fr

189 Lipoprotein lipase (LpL) hydrolyzes triglycerides of cir

190 ectin (Adipoq) promoter drives expression of lipoprotein lipase (LPL) in adipocytes to potentially in

191 ol, we investigated whether lipid uptake via lipoprotein lipase (LPL) in astrocytes is required to ce

192 The relative activity of lipoprotein lipase (LPL) in different tissues controls t

193 nd found that mRNA and protein expression of lipoprotein lipase (LPL) in skeletal muscle was signific

194 The maturation of lipoprotein lipase (LPL) into a catalytically active enz

195 Lipoprotein lipase (LPL) is a 448-amino-acid head-to-tai

196 Lipoprotein lipase (LPL) is a candidate gene for compone

197 Lipoprotein lipase (LPL) is a key enzyme for lipoprotein

198 Lipoprotein lipase (LPL) is a key enzyme in lipoprotein

199 Lipoprotein lipase (LPL) is a key enzyme in the hydrolys

200 Lipoprotein lipase (LPL) is active in capillaries, where

201 Lipoprotein lipase (LPL) is an enzyme responsible for cl

202 Lipoprotein lipase (LPL) is an important enzyme in adipo

203 Lipoprotein lipase (LPL) is central to triglyceride meta

204 Lipoprotein lipase (LPL) is rate limiting in the provisi

205 The enzyme lipoprotein lipase (LPL) is responsible for breaking dow

206 Lipoprotein lipase (LPL) is responsible for the intravas

207 ncreased risk of cardiovascular disease, and lipoprotein lipase (LPL) is the rate-limiting enzyme for

208 ptake, and gene expression in heart-specific lipoprotein lipase (LpL) knock-out (hLpL0), CD36 knock-o

209 ass B type I levels but paralleled increased lipoprotein lipase (LPL) levels and LPL distribution in

210 We show that lipoprotein lipase (LPL) may more efficiently hydrolyze

211 lipolytic products produced by the action of lipoprotein lipase (LPL) on circulating triglyceride-ric

212 tty acids derived from the action of cardiac lipoprotein lipase (LPL) on plasma lipoproteins may cont

213 Lipoprotein lipase (LPL) plays a central role in lipid m

214 Lipoprotein lipase (LPL) plays a central role in triglyc

215 Lipoprotein lipase (LPL) plays a rate-limiting role in t

216 Lipoprotein lipase (LpL) provides tissues with triglycer

217 showed that modification of HCV particles by lipoprotein lipase (LPL) reduces HCV infectivity and inc

218 The pattern of lipoprotein lipase (LPL) release into the plasma after a

219 exposing LDL(-) to the key lipolytic enzyme lipoprotein lipase (LPL) reversed these responses, inhib

220 of plasma triglyceride metabolism, binds to lipoprotein lipase (LPL) through its N-terminal coiled-c

221 The binding of lipoprotein lipase (LPL) to GPIHBP1 focuses the intravas

222 gress on GPIHBP1, a molecule that transports lipoprotein lipase (LPL) to the capillary lumen, and dis

223 Lipoprotein lipase (LPL) undergoes spontaneous inactivat

224 We investigated the association of the lipoprotein lipase (LPL) variant rs13702 with plasma lip

225 Using RNA in situ hybridization, lipoprotein lipase (LPL) was found to be expressed in en

226 PPARgamma coactivator 1beta (PGC1beta), and lipoprotein lipase (LPL) were among the up-regulated gen

227 Transgenic mice expressing non-transferable lipoprotein lipase (LpL) with a glycosylated phosphatidy

228 in of capillary endothelial cells that binds lipoprotein lipase (LPL) within the interstitial space a

229 in of microvascular endothelial cells, binds lipoprotein lipase (LPL) within the interstitial spaces

230 rotein of capillary endothelial cells, binds lipoprotein lipase (LPL) within the subendothelial space

231 and validate candidate functional SNPs using lipoprotein lipase (LPL), a gene previously associated w

232 A well-known cause is the deficiency of lipoprotein lipase (LPL), a key enzyme in plasma triglyc

233 (betaLPL-TG) or inactivation (betaLPL-KO) of lipoprotein lipase (LPL), a physiologic provider of fatt

234 It is known as an endogenous inhibitor of lipoprotein lipase (LPL), and it modulates lipid deposit

235 icron-sized n-6 TG emulsions is modulated by lipoprotein lipase (LPL), apoE, LDL-R, and lactoferrin-s

236 e metabolism, fatty acid synthase (FAS), and lipoprotein lipase (LPL), as well as on circulating leve

237 adipocyte fatty acid-binding protein (aP2), lipoprotein lipase (LPL), fatty acid synthase (FAS), hor

238 a (PPARgamma), leptin, adiponectin, adipsin, lipoprotein lipase (LPL), Glut 1, Glut 3, but not Glut 4

239 treatment lowered plasma TGs in mice lacking lipoprotein lipase (LPL), hepatic heparan sulfate proteo

240 al, mechanism of action, and relation to the lipoprotein lipase (LPL), however, remain elusive.

241 Three genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and pro

242 physiologically important proteins, such as lipoprotein lipase (LPL), leptin, adipsin, Acrp30, etc.

243 y acids and SNPs in apolipoprotein J (APOJ), lipoprotein lipase (LPL), macrophage scavenger receptor

244 fficient triglyceride clearance catalyzed by lipoprotein lipase (Lpl), partly due to defective expres

245 ssion of glucose transporter type 4 (GLUT4), lipoprotein lipase (LpL), peroxisome proliferator-activa

246 ed primarily by hormone-sensitive lipase and lipoprotein lipase (LPL), respectively.

247 didate gene that emerged from our screen was lipoprotein lipase (Lpl), which encodes an enzyme that f

248 Overexpression of the gene encoding lipoprotein lipase (LPL), which was upregulated in zebra

249 cids associated with albumin or derived from lipoprotein lipase (LpL)-mediated hydrolysis of lipoprot

250 lting in hypertriglyceridemia, by inhibiting lipoprotein lipase (LPL)-mediated hydrolysis of plasma t

251 Lipoprotein lipase (LPL)-mediated lipolysis of triglycer

252 circulating triglycerides (TG) by inhibiting lipoprotein lipase (LPL).

253 ceride (TG) metabolism in part by inhibiting lipoprotein lipase (LPL).

254 confers upon those cells the ability to bind lipoprotein lipase (LPL).

255 modeled the fate of fatty acids released by lipoprotein lipase (LPL).

256 amily, including endothelial lipase (EL) and lipoprotein lipase (LPL).

257 cles marginate when they bind to endothelial lipoprotein lipase (LpL).

258 cipation of LRP in the endocytosis of HL and lipoprotein lipase (LPL).

259 identity with endothelial lipase (LIPG) and lipoprotein lipase (LPL).

260 through regulation of the bioavailability of lipoprotein lipase (LPL).

261 uptake is critically dependent on the enzyme lipoprotein lipase (LPL).

262 ecurrent pancreatitis due to a deficiency in lipoprotein lipase (LPL).

263 ng triglyceride (TG)-derived fatty acids via lipoprotein lipase (LpL).

264 roteins which exhibit stimulatory effects on lipoprotein lipase (LPL).

265 Lipoprotein lipase-mediated (LPL-mediated) lipolysis of

266 effects on plasma lipolytic activity through lipoprotein lipase-mediated clearance, as well as stimul

267 iglyceride-derived fatty acids, generated by lipoprotein lipase-mediated hydrolysis of triglycerides,

268 CD36 expression in macrophage, inhibition of lipoprotein lipase-mediated lipolysis, decreased adipone

269 lipogenesis by impacting both endocytic and lipoprotein lipase-mediated metabolic pathways.

270 gptl4 is a secreted protein and inhibitor of lipoprotein lipase-mediated plasma triglyceride clearanc

271 giopoietin-like 4 (ANGPTL4), an inhibitor of lipoprotein lipase-mediated plasma triglyceride clearanc

272 In contrast, liver-lipoprotein lipase mice had a 2-fold increase in liver t

273 Muscle-lipoprotein lipase mice had a 3-fold increase in muscle

274 sin heavy-chain promoter upstream of a human lipoprotein lipase minigene construct with a glycosylpho

275 The action of lipoprotein lipase on triglyceride-rich lipoproteins gen

276 ylation of the zeta-associated protein gene, lipoprotein lipase overexpression, telomere length, and

277 of low-density lipoprotein cholesterol, the lipoprotein lipase pathway or circulating lipoprotein(a)

278 ugh the lepidopteran ESP/YP2s are related to lipoprotein lipases, previous attempts to directly demon

279 SUV39H1 to the PPAR response element of the lipoprotein lipase promoter and decreased acetylation of

280 ted receptor gamma-responsive element of the lipoprotein lipase promoter in the context of the local

281 te morphology or in the expression levels of lipoprotein lipase, proxisomal proliferation-activating

282 Lipid droplet formation was reduced when lipoprotein lipase-released fatty acids were bound by BS

283 of the "regulatory module" with the "lid" of lipoprotein lipase resulted in enzymatically inactive pr

284 arterial wall that promote retention such as lipoprotein lipase, secretory sphingomyelinase, and secr

285 hat sphingomyelin and a proteoglycan mediate lipoprotein lipase sorting in the TGN.

286 eted disruption of the TG-hydrolyzing enzyme lipoprotein lipase specifically in the nucleus accumbens

287 low HDL-C syndromes in humans include APOC3, lipoprotein lipase, sphingomyelin phosphodiesterase 1, a

288 stigate the role of Angptl4, an inhibitor of lipoprotein lipase that is induced by >3-fold in the hea

289 t the higher dipterans did not requisition a lipoprotein lipase to replace Vg as a yolk protein precu

290 Mice deficient for lipoprotein lipase treated with D-galactose did not reta

291 okines, favoring insulin resistance, whereas lipoprotein lipase was down-regulated.

292 or-activated receptor gamma (PPARgamma), and lipoprotein lipase was elevated in LGD1069-responding tu

293 eling for carboxymethyllysine, biglycan, and lipoprotein lipase was found in D-galactose-treated mice

294 ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations

295 t P. gingivalis bacterial cells treated with lipoprotein lipase were attenuated in their ability to a

296 The fed/fasted activities of adipose tissue lipoprotein lipase were not significantly different betw

297 muscle- and liver-specific overexpression of lipoprotein lipase were studied during a 2-h hyperinsuli

298 mice with an adenovirus-expressing wild-type lipoprotein lipase, whereas an inactive lipoprotein lipa

299 c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation

300 This, together with FoxO1 induction of lipoprotein lipase, would promote the reliance on fatty